For more information, please contact Paul Armentano, NORML Senior Policy Analyst, at (202) 483-5500.
Full text of studies, "Treatment for hepatitis C virus and cannabis use in illicit drug user patients: implications and questions" and "Cannabis use improves retention and virological outcomes in patients treated for hepatitis C," are available in the October issue of the European Journal of Gastroenterology & Hepatology.
Additional information on cannabinoids and hepatitis C is available in NORML's new report, "Emerging Clinical Applications for Cannabis," online at: http://www.norml.org/index.cfm?Group_ID=7002. (訳)
For more information, please contact Allen St. Pierre, NORML Executive Director, at (202) 483-5500.
For a comprehensive breakdown and analysis of US marijuana arrests, please see NORML's report: "Crimes of Indiscretion: Marijuana Arrests in the United States," at: http://www.norml.org/index.cfm?Group_ID=6411
Full text of studies, "Treatment for hepatitis C virus and cannabis use in illicit drug user patients: implications and questions" and "Cannabis use improves retention and virological outcomes in patients treated for hepatitis C," are available in the October issue of the European Journal of Gastroenterology & Hepatology.
Additional information on cannabinoids and hepatitis C is available in NORML's new report, "Emerging Clinical Applications for Cannabis," online at: http://www.norml.org/index.cfm?Group_ID=7002. (訳)
Source: http://www.norml.org/index.cfm?Group_ID=7046